Nutrients 2021. Erinacine A-Enriched Hericium erinaceus Mycelium Delays Progression of Age-Related Cognitive Decline in SAMP8 Mice (PMID 34684662).
Rationale
This work is the preclinical foundation of the "human" erinacine line: the same research program (erinacine A-enriched mycelium, EAHEM) that led to the pilot RCT in early Alzheimer's disease (our card ezhovik-alzheimer-2020, PMID 32581767). Here the question was whether EAHEM slows normal age-related brain aging — not disease, but degenerative senescence.
Methods
Three-month-old SAMP8 mice (an accelerated-senescence model) were divided into three dose groups: 108, 215 and 431 mg/kg/day of EAHEM in feed for 12 weeks. In week 12, learning and memory were assessed by single-trial passive and active avoidance tests. After sacrifice, amyloid plaques, iNOS activity (inflammation), TBARS (lipid peroxidation) and 8-OHdG (oxidative DNA damage) were analyzed in brain tissue.
Results
- Even the lowest dose of 108 mg/kg/day significantly improved learning and memory in both avoidance tests.
- In all three dose groups, iNOS, TBARS and 8-OHdG fell significantly and dose-dependently — the higher the dose, the lower the brain inflammation and oxidative stress markers.
- The authors conclude that EAHEM improves learning/memory and delays degenerative brain aging in mice.
Conclusions
The experiment shows a mechanistically plausible profile: reduced inflammatory iNOS and two independent oxidative-damage markers coinciding with behavioral improvement. The dose-dependence strengthens the case — the effect does not look like a single-group artifact.
Caveats
- These are mice — and a genetically modified accelerated-aging line at that: no direct extrapolation to humans. Human erinacine A data come from separate small pilot studies.
- The 108 mg/kg mouse dose does not convert directly into a household dose — murine metabolism and erinacine bioavailability differ.
- Groups lack placebo control in the clinical sense (standard for preclinical work), but dose-dependence partly compensates.
- This card replaces an unverifiable citation about a "24-week phase IIb RCT, n=88, Nutritional Neuroscience 2024" — no such work exists in PubMed; the current source was verified directly.